Short answer. In the US, cannabis plants and what's made from them can be protected three ways: utility patents (plants, traits, extracts and methods), plant patents (a specific asexually reproduced variety) and plant variety protection certificates (seed-propagated varieties; hemp accepted since 2019) [1][5][6][11]. Canada and the EU grant plant breeders' rights too. All of these are public records. Legal commentators worry that thin documented prior art makes broad claims easier to obtain and harder to challenge [7][8]. The answer that doesn't need a lawyer is public, dated documentation of what already exists, which is what GB-IDs and open sharing provide.
House position: preservation is why GenetixBay exists. Patents plus consolidation can narrow the commons, and a narrower commons means a narrower gene pool. We don't speculate about anyone's motives, and we don't accuse companies. We document: every line, every cut, every male, with dates and evidence, in the open, so the shared heritage of cannabis stays shared.
The three kinds of protection (US)
| Type | Covers | Term | Example on public record |
|---|---|---|---|
| Utility patent | A new, useful, non-obvious invention: can include a plant with defined traits, a breeding method, an extract or a use | 20 years from filing | US 9,095,554 (2015): claims a hybrid cannabis plant with a defined genotype, terpene profile (myrcene not dominant), terpene oil content and CBD content, with deposited seed [1] |
| Plant patent | One distinct, asexually reproduced variety (a clone) | 20 years from filing | US PP27,475 'Ecuadorian Sativa' (2016), reported as the first US cannabis plant patent [5] |
| Plant variety protection (PVP) | A distinct, uniform, stable seed-propagated variety | 20 years | USDA began accepting hemp applications on 24 April 2019 [6] |
A historical oddity: the US government itself holds a utility patent on cannabinoids as antioxidants and neuroprotectants (US 6,630,507, 2003) [4].
What a patent can and can't do
- It can stop others making, using or selling what the claims cover, for the term of the patent, where it's in force.
- It can't reach backwards: something publicly known before the filing date is prior art and can't validly be claimed.
- Claims are read narrowly against their exact wording. A patent on a plant with a defined set of traits doesn't cover every plant with one of those traits.
- Whether home growers could ever be affected depends on the claims, the jurisdiction and the facts. We're not lawyers; for anything specific, ask one.
The court case people cite
The best-known US dispute concerned US 9,730,911, a patent on cannabis extracts and formulations. In the district court (Colorado, filed 2018), the court in 2019 declined to throw out the claims as covering a natural phenomenon, reported as the first cannabis patent case decided in federal court. The infringement claims were later dismissed with prejudice by agreement. On appeal over attorney fees, the Federal Circuit in 2023 affirmed that the case wasn't "exceptional" enough to award fees [2][3]. That's the record; we draw no conclusions about any party.
The worry about the commons
Commentators make three documented points [7][8]:
- Thin prior art. Decades of prohibition meant little formal publication on cannabis varieties, chemistry and breeding. Patent examiners search published literature; oral knowledge and unpublished grow records are hard to cite.
- Rising filings. Patent and breeders'-rights filings on cannabis rose sharply once legal markets opened [7].
- Breadth. Claims framed around trait combinations (chemotype, terpene profile) could overlap with plants bred or kept long before, if nobody can prove it.being reviewed
The open responses
| Response | What it is | Status |
|---|---|---|
| Prior-art databases | Public, dated genetic and chemical records of existing varieties, so examiners and challengers can find them | One prominent non-profit prior-art project announced its dissolution in 2019 [10]; commercial genotype registries also publish dated genotypes |
| Defensive publication | Publishing a variety's description, chemistry and genotype openly, with a date, so it becomes prior art | Anyone can do it; the record has to be findable and dated |
| Open-source seed pledges | Breeders pledge that a variety and its derivatives stay free to use, breed and share | The main open-source seed initiative accepts cannabis materials only up to 0.3 % THC [9] |
| Plant breeders' rights with breeder exemptions | PVP-style protection usually lets other breeders use the variety for further breeding | Built into PVP law [11] |
GenetixBay's answer: preserve, document, share
- GB-IDs are dated, public evidence. Every registered line, cut and male carries a timestamped record: who, when, where from, photos, journals, lab results and, where available, genotype data (see documenting lineage). That's exactly the kind of record prior-art searches need.
- Open by default. Knowledge-base text and trial results are CC BY-SA. Members choose what to publish about their genetics; the archive keeps it permanently.
- Preservation before it's gone. Wanted-line and revival programmes, clone backups and the Stud Book for males keep diversity alive (see clone-only preservation and landraces of the world).
- No legal advice. If you think a patent affects you, talk to a patent attorney in your jurisdiction.
Common mistakes
- "They patented Kush." Patents claim specific, defined things; read the claims before repeating a headline.
- Assuming a variety is protected (or unprotected) without checking the patent and PVP databases.
- Keeping your line's history only in your head or a private chat. Undated, unpublished knowledge can't serve as prior art.
Evidence
- The existence and content of the patents, certificates and case cited: public record [1]–[6][11].
- Legal commentary on prior art and the commons: Supported as commentary [7][8]; its practical effect on growers is Contested.
- Documentation as a defence: Supported in principle (prior art defeats novelty); how often it has been used for cannabis isn't documented.
